- Home
- RVSN vs QNRX Comparison
RVSN vs QNRX Comparison
Compare RVSN & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVSN | QNRX |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 9.2M |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | RVSN | QNRX |
|---|---|---|
| Price | $2.93 | $4.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $20.71 |
| AVG Volume (30 Days) | 15.1K | ★ 40.8K |
| Earning Date | 08-26-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $169.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $3.25 |
| 52 Week High | $9.39 | $23.50 |
Technical Indicators
Market Signals| Indicator | RVSN | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.31 | 27.69 |
| Support Level | $0.24 | $3.25 |
| Resistance Level | $5.19 | $4.50 |
| Average True Range (ATR) | 0.27 | 0.51 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 8.92 | 3.60 |
Price Performance
Historical ComparisonAbout RVSN Rail Vision Ltd.
Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.